AstraZeneca : Truqap plus Faslodex approved in Japan for patients with advanced HR-positive breast cancer -March 27, 2024 at 03:09 am EDT : vimarsana.com

First and only AKT inhibitor approved in Japan for breast cancer patients with specific biomarker alterations

Approval based on CAPItello-291 results which showed...

Related Keywords

China , Japan , Canada , United Kingdom , Cambridge , Cambridgeshire , Japanese , Daiichi Sankyo , Astrazeneca Truqap , Nasdaq , National Comprehensive Cancer Network , European Union , Astrazeneca , Merck Co Inc , Investor Relations Team , World Health Organization , Institute Of Cancer Research , Japanese Ministry Of Health , End Results Program , National Cancer Institute , Cancer Research Technology , Japanese Ministry , New England Journal , Astex Therapeutics , Cancer Research , Cancer Research Technology Limited , Rare Diseases , Hormone Receptor Positive Advanced Breast , Accessed March , End Results , Genetic Alterations , Everolimus Benefit , Hormone Receptor Positive , Human Epidermal Growth Factor Receptor , Negative Advanced Breast Cancer , Results From , Overall Survival , Plus Endocrine Therapy , Therapy Alone , Advanced Hormone Receptor Positive , Breast Cancer , Emerging Therapeutic , Clin Cancer , Comprehensive Cancer , Clinical Practice Guidelines , Markets ,